NL-OMON54156招募中不适用
ivolumab dose optimization during nivolumab therapy in melanoma patients after achieving a complete, partial or stable response (NIVOPTIMIZE-trial) - NIVOPTIMIZE-trial
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 34
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •1. Age >= 18 years
- •2. Advanced or metastatic melanoma or renal cell carcinoma
- •3. Current treatment with nivolumab in a 480 mg or 6mg/kg, 4 weekly scheme
- •4. Documented confirmed and ongoing CR, PR or SD according to RECIST v1.1
- •5. On treatment for at least 6 months
排除标准
- •- Unable to draw blood for study purposes
- •- Patients willing to participate or already included in the SAFE-STOP trial
研究者
相似试验
进行中（未招募）
1 期
ivolumab dose optimization in patients with a complete, partial or stable response (NIVOPTIMIZE-trial)Patients with advanced or metastatic melanoma or renal cell carcinoma treated with nivolumab monotherapy in a 480mg or 6 mg/kg 4 weekly scheme (either from start or after combination therapy with ipilimumab), have a confirmed CR, PR or SD, are at least 6 months on treatment and are willing to receive 3 reduced doses of 240 mgEUCTR2021-001707-32-NLErasmus Medical Center Rotterdam91
进行中（未招募）
1 期
ivolumab dose optimization in patients with a complete, partial or stable response (NIVOPTIMIZE-trial)CTIS2024-516718-39-00Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)34
已完成
1 期
Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver CancerStage IIIA Hepatocellular CarcinomaStage IIIB Hepatocellular CarcinomaStage IIIC Hepatocellular CarcinomaStage IVA Hepatocellular CarcinomaStage IVB Hepatocellular CarcinomaNCT02837029Northwestern University27
已完成
4 期
A Phase 4 Study of Combination Nivolumab and Ipilimumab in Patients with Advanced Renal Cell Carcinoma in IndiaCTRI/2020/10/028626BRISTOL MYERS SQUIBB INDIA PRIVATE LIMITED101
尚未招募
2 期
ow dose immunotherapy with Chemotherapy prior to Standard treatment of chemotherapy plus radiation in advanced Carcinoma CervixCTRI/2024/07/071051ICMR